C12Y 207/11001
Non-specific serine/threonine protein kinase , i.e. casein kinase or checkpoint kinase
Official title: Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
C12Y207/11001 (Non-specific serine/threonine protein kinase , i.e. casein kinase or checkpoint kinase) appears on 265 US grants and 622 published applications in this corpus.
Search patents in C12Y- Granted patents
- 265
- Published applications
- 622
- Assignees
- 320
- Inventors
- 1,168
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 1 |
| 2002 | 5 | 4 |
| 2003 | 1 | 3 |
| 2004 | 2 | 10 |
| 2005 | 0 | 43 |
| 2006 | 1 | 4 |
| 2007 | 0 | 8 |
| 2008 | 2 | 9 |
| 2009 | 3 | 13 |
| 2010 | 8 | 14 |
| 2011 | 6 | 10 |
| 2012 | 6 | 11 |
| 2013 | 2 | 15 |
| 2014 | 10 | 17 |
| 2015 | 14 | 44 |
| 2016 | 15 | 43 |
| 2017 | 28 | 39 |
| 2018 | 17 | 27 |
| 2019 | 23 | 40 |
| 2020 | 22 | 26 |
| 2021 | 21 | 28 |
| 2022 | 19 | 51 |
| 2023 | 14 | 40 |
| 2024 | 16 | 52 |
| 2025 | 16 | 40 |
| 2026 | 13 | 30 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Muscle targeting complexes and formulations for treating myotonic dystrophy4 Aug 2026US 12,697,394 B2Dyne Therapeutics, Inc.
- Microorganisms for diterpene production23 Jun 2026US 12,662,680 B2Cargill, Incorporated
- Use of metformin and analogs thereof to reduce RAN protein levels in the treatment of neurological disorders9 Jun 2026US 12,648,917 B2University of Florida Research Foundation, Inc.
- Carrier peptide fragment and use thereof5 May 2026US 12,617,817 B2Toagosei Co., Ltd.
- G12-specific designer receptor exclusively activated by designer drugs28 Apr 2026US 12,612,442 B2Cell Networks GmbH
- Precision immunosuppression as prevention and therapy for graft-versus-host disease8 Oct 2026US 2026/0308592 A1
- Tropane Alkaloid (TA) Producing Non-Plant Host Cells, and Methods of Making and Using the Same17 Sep 2026US 2026/0275357 A1The Board of Trustees of the Leland Stanford Junior University
- Methods for inhibiting macrophage neurotoxicity17 Sep 2026US 2026/0276627 A1Ajou University Industry-Academic Cooperation Foundation
- Compounds targeting dmpk for the treatment of myotonic dystrophy10 Sep 2026US 2026/0263602 A1Novartis AG
- Chk1-targeting sirnas chemically modified with gemcitabine10 Sep 2026US 2026/0265754 A1Sirnaomics, Inc.
Most cited
By later US patents
- Interfering RNA molecules134US 7,452,987 B2Silence Therapeutics GmbH · 2008
- Methods and compositions for generating bioactive assemblies of increased complexity and uses128US 7,534,866 B2IBC Pharmaceuticals, Inc. · 2009
- Methods and compositions for generating bioactive assemblies of increased complexity and uses112US 7,906,121 B2IBC Pharmaceuticals, Inc. · 2011
- Interfering RNA molecules77US 9,222,092 B2Silence Therapeutics GmbH · 2015
- Interfering RNA molecules63US 7,893,245 B2Silence Therapeutics GmbH · 2011